160 related articles for article (PubMed ID: 34455614)
21. Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis.
Sandoval GJ; Pulice JL; Pakula H; Schenone M; Takeda DY; Pop M; Boulay G; Williamson KE; McBride MJ; Pan J; St Pierre R; Hartman E; Garraway LA; Carr SA; Rivera MN; Li Z; Ronco L; Hahn WC; Kadoch C
Mol Cell; 2018 Aug; 71(4):554-566.e7. PubMed ID: 30078722
[TBL] [Abstract][Full Text] [Related]
22. Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate.
Mi J; Hooker E; Balog S; Zeng H; Johnson DT; He Y; Yu EJ; Wu H; Le V; Lee DH; Aldahl J; Gonzalgo ML; Sun Z
J Biol Chem; 2018 Dec; 293(52):20123-20136. PubMed ID: 30401749
[TBL] [Abstract][Full Text] [Related]
23. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT
Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of ERG expression and PTEN loss in a Brazilian prostate cancer cohort.
Morais CE; Gurgel DC; Teixeira AC; Mattos TVA; Silva AVAD; Tavora F
Braz J Med Biol Res; 2019; 52(12):e8483. PubMed ID: 31826177
[TBL] [Abstract][Full Text] [Related]
25. SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation.
Thomsen MK; Ambroisine L; Wynn S; Cheah KS; Foster CS; Fisher G; Berney DM; Møller H; Reuter VE; Scardino P; Cuzick J; Ragavan N; Singh PB; Martin FL; Butler CM; Cooper CS; Swain A;
Cancer Res; 2010 Feb; 70(3):979-87. PubMed ID: 20103652
[TBL] [Abstract][Full Text] [Related]
26. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.
Song H; Zhang B; Watson MA; Humphrey PA; Lim H; Milbrandt J
Oncogene; 2009 Sep; 28(37):3307-19. PubMed ID: 19597465
[TBL] [Abstract][Full Text] [Related]
27. TMPRSS2-ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer.
Fisher KW; Zhang S; Wang M; Montironi R; Wang L; Baldrige LA; Wang JY; MacLennan GT; Williamson SR; Lopez-Beltran A; Cheng L
Mol Carcinog; 2017 Mar; 56(3):814-820. PubMed ID: 27500376
[TBL] [Abstract][Full Text] [Related]
28. ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis.
Bose R; Karthaus WR; Armenia J; Abida W; Iaquinta PJ; Zhang Z; Wongvipat J; Wasmuth EV; Shah N; Sullivan PS; Doran MG; Wang P; Patruno A; Zhao Y; ; Zheng D; Schultz N; Sawyers CL
Nature; 2017 Jun; 546(7660):671-675. PubMed ID: 28614298
[TBL] [Abstract][Full Text] [Related]
29. Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma.
Ratnacaram CK; Teletin M; Jiang M; Meng X; Chambon P; Metzger D
Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2521-6. PubMed ID: 18268330
[TBL] [Abstract][Full Text] [Related]
30. Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer.
Wu Z; He B; He J; Mao X
Prostate; 2013 May; 73(6):596-604. PubMed ID: 23060044
[TBL] [Abstract][Full Text] [Related]
31. Transcriptional landscape of PTEN loss in primary prostate cancer.
Imada EL; Sanchez DF; Dinalankara W; Vidotto T; Ebot EM; Tyekucheva S; Franco GR; Mucci LA; Loda M; Schaeffer EM; Lotan T; Marchionni L
BMC Cancer; 2021 Jul; 21(1):856. PubMed ID: 34311724
[TBL] [Abstract][Full Text] [Related]
32. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
33. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
[TBL] [Abstract][Full Text] [Related]
34. Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene.
Ribeiro FR; Paulo P; Costa VL; Barros-Silva JD; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
PLoS One; 2011; 6(7):e22317. PubMed ID: 21814574
[TBL] [Abstract][Full Text] [Related]
35. Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers.
Wang Y; Romigh T; He X; Tan MH; Orloff MS; Silverman RH; Heston WD; Eng C
Oncogene; 2011 Oct; 30(42):4327-38. PubMed ID: 21532617
[TBL] [Abstract][Full Text] [Related]
36. RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis.
Bai Y; Yang Y; Yan Y; Zhong J; Blee AM; Pan Y; Ma T; Karnes RJ; Jimenez R; Xu W; Huang H
Theranostics; 2019; 9(12):3459-3475. PubMed ID: 31281490
[No Abstract] [Full Text] [Related]
37. Role of lncRNAs in prostate cancer development and progression.
Weiss M; Plass C; Gerhauser C
Biol Chem; 2014 Nov; 395(11):1275-90. PubMed ID: 25153594
[TBL] [Abstract][Full Text] [Related]
38. Tgfbr2 inactivation facilitates cellular plasticity and development of Pten-null prostate cancer.
Zhao W; Zhu Q; Tan P; Ajibade A; Long T; Long W; Li Q; Liu P; Ning B; Wang HY; Wang RF
J Mol Cell Biol; 2018 Aug; 10(4):316-330. PubMed ID: 29228234
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-6 and oncostatin-M synergize with the PI3K/AKT pathway to promote aggressive prostate malignancy in mouse and human tissues.
Smith DA; Kiba A; Zong Y; Witte ON
Mol Cancer Res; 2013 Oct; 11(10):1159-65. PubMed ID: 23867565
[TBL] [Abstract][Full Text] [Related]
40. Protocols for Studies on TMPRSS2/ERG in Prostate Cancer.
Pakula H; Linn DE; Schmidt DR; Van Gorsel M; Vander Heiden MG; Li Z
Methods Mol Biol; 2018; 1786():131-151. PubMed ID: 29786791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]